We are live on ! Find out more

273 hedge funds and large institutions have $5.96B invested in DexCom in 2017 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 73 increasing their positions, 112 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more call options, than puts

Call options by funds: $31.8M | Put options by funds: $15.4M

20% more capital invested

Capital invested by funds: $4.97B → $5.96B (+$987M)

7.53% more ownership

Funds ownership: 470.43%477.97% (+7.5%)

3% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 59

1% less funds holding

Funds holding: 275273 (-2)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

35% less repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 112

Holders
273
Holders Change
-2
Holders Change %
-0.73%
% of All Funds
6.19%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
61
Increased
73
Reduced
112
Closed
59
Calls
$31.8M
Puts
$15.4M
Net Calls
+$16.4M
Net Calls Change
+$4.52M

DXCM Hedge Fund Activity: Q4 2017 in Review

273 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q4 2017, worth a combined $5.96B — up 20% from $4.97B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new DXCM positions and 59 closed out — a net gain of 2 holders — while 73 added to existing stakes and 112 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $286M. The largest seller was Fidelity Investments, cutting an estimated $225M.

  • 273 institutional investors held DexCom (DXCM) as of Q4 2017, down from 275 in Q3 2017.
  • Funds reported $5.96B of DexCom stock for Q4 2017, up 20% quarter-over-quarter.
  • 61 funds opened new DexCom positions in Q4 2017 and 59 closed out, a net change of +2 holders.
  • The largest DexCom buyer in Q4 2017 was T. Rowe Price Associates, an estimated $286M added.
  • The largest DexCom seller in Q4 2017 was Fidelity Investments, an estimated $225M sold.

Based on aggregated 13F filings for Q4 2017.